Alcon (SIX/NYSE:ALC) announced today that it launched the Clareon family of intraocular lenses (IOLs) in the U.S.
Geneva, Switzerland-based Alcon designed the Clareon family of lenses with a glistening-free IOL material with the lowest levels of haze and subsurface nanoglistenings (SSNGs) compared to leading competitors’ IOLs, according to a news release.
The company describes Clareon as offering sharp, crisp vision with a proprietary edge for helping to reduce glare and posterior capsular opacification. At the same time, its Stableforce haptics provide strong axial and rotational stability. Clareon IOLs are inserted using the next-generation, reusable Clareon Monarch IV delivery system.
Alcon also made its Clareon Monofocal available in the next-generation, automated, single-use delivery system called AutonoMe. Clareon Toric will be available in the U.S. later this year, and the company will roll out the Clareon family of IOLs in international markets throughout 2022 and 2023.
“We are proud to offer our latest IOL technology in the U.S. and other countries across the globe. At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients,” Alcon President of Global Business and Innovation Ian Bell said in the release. “Clareon is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems—to deliver exceptional, long-lasting clarity.”